Table 2.
Mean change in BCVA after 12 months’ treatment with anti-VEGF therapy
| Drug | Study | Design | Total sample size (patients) | Patients receiving anti-VEGF treatment | Mean change in BCVA (ETDRS letters) | Injection number over 12 months (mean) | OCEBM level of evidence55 |
|---|---|---|---|---|---|---|---|
| Ranibizumab | RADIANCE52 | Phase III, randomised, double masked, active controlled, multicentre | 277 | 106* | 13.8 | 4.6 | 2 |
| 116† | 14.4 | 3.5 | |||||
| REPAIR53 | Phase II, prospective, open label, multicentre | 65 | 65 | 13.8 | 3.6 | 4 | |
| Franqueira et al 201257 | Retrospective case series | 39 | 39 | 4.3 | 4.1 | 4 | |
| Monés et al 200959 | Prospective case series | 23 | 23 | 9.5 | 1.5 | 4 | |
| Silva et al 201060 | Prospective case series, multicentre | 32 | 32 | 8 | 3.6 | 4 | |
| Lai et al 200962 | Retrospective case series | 16 | 16 | 15‡ | 3.8 | 4 | |
| Bevacizumab | Ikuno et al 200964 | Retrospective case series | 63 | 63 | 11.5‡ | 2.4 | 4 |
| Chan et al 200965 | Prospective case series | 29 | 29 | 12‡ | 3.6 | 4 | |
| Gharbiya et al 200966 | Prospective case series | 20 | 20 | 18.2 | 4.0 | 4 | |
| Ruiz-Moreno et al 201167 | Prospective, comparative, non-randomised multicentre | 38 | 18§ | 6.3 | 3.2 | 4 | |
| 20¶ | 7.2 | 1.7 | |||||
| Ruiz-Moreno et al 201068 | Retrospective case series, multicentre | 107 | 107 | 8.7 | 1†† | 4 | |
| Ruiz-Moreno et al 2011, 201369 70 | Prospective, randomised, multicentre | 55 | 25 | 11.2 | 3.5 | 3 | |
| Iacono et al 201171 | Prospective case series | 30 | 30 | 3.8 | 4.7 | 4 | |
| Gharbiya et al 201272 | Prospective case series | 30 | 30 | 16.4 | 4.1 | 4 | |
| Hayashi et al 201273 | Prospective case series | 69 | 69 | 10.5‡ | NR‡‡ | 4 | |
| Hayashi et al 200974 | Prospective case series | 156 | 43 | 11.5‡ | 1.6 | 4 |
OCEBM levels of evidence grades are as follows: 1: systematic review of randomised trials; 2: randomised trial; 3: non-randomised controlled cohort/follow-up study; 4: case series, case control, or historical controlled study; 5: mechanism-based reasoning.
*Retreatment according to visual acuity stabilisation criteria.
†Retreatment according to disease activity criteria.
‡Approximate ETDRS changes, based on reported logMAR values.
§Patients received three monthly loading doses.
¶Patients received one loading dose.
††For 60% of patients.
‡‡1.8 injections over 2 years.
BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; logMAR, logarithm of the minimum angle of resolution; OCEBM, Oxford Centre for Evidence-Based Medicine; NR, not reported; VEGF, vascular endothelial growth factor.